98%
921
2 minutes
20
Accurate prediction of treatment time is critical in stereotactic radiosurgery (SRS) for optimizing patient scheduling and workflow efficiency. The ZAP-X system (ZAP Surgical Systems, Inc., San Carlos, CA), the newest cranial SRS platform, provides a built-in estimate of treatment time but often underestimates the actual treatment duration. This study aimed to develop a robust predictive model for ZAP-X treatment time, improving accuracy and reliability. Prospective data of 200 patients treated with ZAP-X SRS at Jersey Shore University Medical Center including timing metrics, treatment planning variables, and clinical factors were analyzed. Random Forest regression identified the most critical factors influencing treatment time. Subsequently, Ridge Regression was applied to develop a predictive model, with 10-fold cross-validation used for model tuning and validation. Random Forest analysis identified setup time and gantry time as the most influential variables affecting the treatment duration, followed by the number of beams, number of isocenters, dose, and target number. The Ridge Regression model demonstrated strong predictive performance (R² = 0.984, MAE = 1.94 minutes, RMSE = 2.49 minutes), significantly surpassing the ZAP-X system's internal estimates. The model's accuracy can be attributed to its ability to account for procedural variability, particularly in setup time. The Ridge Regression model provides a highly accurate and interpretable method for predicting ZAP-X treatment time, outperforming the system's internal calculations. This model has immediate clinical utility for improving patient scheduling and resource management in SRS. Future work should focus on validating the model across institutions and adapting it to evolving ZAP-X technology.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296257 | PMC |
http://dx.doi.org/10.7759/cureus.86748 | DOI Listing |
J Med Internet Res
September 2025
School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, Republic of Korea.
Background: Owing to the unique characteristics of digital health interventions (DHIs), a tailored approach to economic evaluation is needed-one that is distinct from that used for pharmacotherapy. However, the absence of clear guidelines in this area is a substantial gap in the evaluation framework.
Objective: This study aims to systematically review and compare the economic evaluation literature on DHIs and pharmacotherapy for the treatment of depression.
JMIR Hum Factors
September 2025
KK Women's and Children's Hospital, Singapore, Singapore.
Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.
View Article and Find Full Text PDFACS Sens
September 2025
METU MEMS Center, Ankara 06530, Türkiye.
Cardiovascular diseases (CVDs) remain a leading cause of death, particularly in developing countries, where their incidence continues to rise. Traditional CVD diagnostic methods are often time-consuming and inconvenient, necessitating more efficient alternatives. Rapid and accurate measurement of cardiac biomarkers released into body fluids is critical for early detection, timely intervention, and improved patient outcomes.
View Article and Find Full Text PDFJ Oncol Pharm Pract
September 2025
Hematology/Oncology, Scripps Clinic, La Jolla, USA.
IntroductionDaratumumab is a therapeutic cornerstone of the management of multiple myeloma, exerting its anti-myeloma activity through targeting of the cell surface glycoprotein CD38 on plasma cells. While originally given intravenously, the subcutaneous formulation, daratumumab hyaluronidase injection (Dara SC), has been associated with non-inferior efficacy and lower infusion-related reaction rates (IRRs) in the treatment of multiple myeloma and light chain amyloidosis. A noted benefit of Dara SC is a short administration time; however, the optimal observation time post injection to ensure patient safety is unclear from the drug labeling.
View Article and Find Full Text PDFCereb Cortex
August 2025
Department of Psychology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany.
The human auditory system must distinguish relevant sounds from noise. Severe hearing loss can be treated with cochlear implants (CIs), but how the brain adapts to electrical hearing remains unclear. This study examined adaptation to unilateral CI use in the first and seventh months after CI activation using speech comprehension measures and electroencephalography recordings, both during passive listening and an active spatial listening task.
View Article and Find Full Text PDF